Find a Trial

Trial Summary


Protocol No.CTO-IPH4102-102
StatusOPEN TO ACCRUAL
Principal InvestigatorDave, Utpal
ScopeNational
PhasePhase I
Age GroupAdult
TitleA multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2
DescriptionThis is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Relapsed and/or refractory stage IVA, IVB SS who have received at least two prior systemic therapies;
  • Prior treatment with mogamulizumab;
  • Patients should have blood stage B2 at screening based on central evaluation by flow cytometry;
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesNon-Hodgkin's Lymphoma
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632
    Email: iutrials@iu.edu